Add to MyPages

This page will be saved to Cincinnati Children's MyPages, a collection of your favorite places. You can view, organize, or delete your favorites at any time.

Page Title:

Description: (optional)

E-mail this page

(All fields required)

Recipient's e-mail address

Please enter a valid e-mail.

Your name

Please enter your name.

Your e-mail

Please enter a valid e-mail.

Share this on:

Sign into CCHMC

User Name

Password

Forgot Password

Biographies

Find another Doctor or Researcher

A photo of Maryam Fouladi.

High Res

Maryam Fouladi, MD, MSc

Medical Director, Neuro-Oncology Program

Cincinnati Children's Principal Investigator, Collaborative Ependymoma Research Network

Professor, UC Department of Pediatrics

Phone: 513-636-4266

Fax: 513-636-3549

Email: maryam.fouladi@cchmc.org

Show All

Biography

Maryam Fouladi, MD, MSc, graduated from the University of Toronto School of Medicine, and completed her pediatric residency and hematology / oncology fellowship training at the Hospital for Sick Children in Toronto, Canada. Dr. Fouladi then completed her neuro-oncology fellowship training at St. Jude Children's Research Hospital, and later completed further training in the molecular pharmacology department at St. Jude before becoming a neuro-oncology faculty member in 2000. She served as the Chair of the Phase I Committee at St. Jude.

Dr. Fouladi moved to Cincinnati Children's in 2008 to direct the neuro-oncology program. She is currently chair for the CNS Tumor New Agent Committee for the Children’s Oncology Group. She is a member of the Steering Committee for the COG CNS Tumor Committee as well as the Developmental Therapeutics group at COG, and is a member of the Collaborative Ependymoma Research Network (CERN). She serves as local and national study chair (through CERN, COG and the Pediatric Brain Tumor Consortium) for clinical trials that test new approaches to treat children with very poor prognosis tumors such as high-grade gliomas and diffuse intrinsic pontine gliomas.

Education and Training

BS: Human Biology, University of Toronto, Toronto, Canada, 1987.

MD: University of Toronto, Toronto, Canada, 1991.

MSc: Institute of Medical Science, University of Toronto, Toronto, Canada, 2002.

Publications

View PubMed Publications

Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. J Pediatr Hematol Oncol. 2011 Aug;33(6):e250-2.

Phillips CL, Miles L, Jones BV, Sutton M, Crone K, Fouladi M. Medulloblastoma with melanotic differentiation: case report and review of the literature. J Neurooncol. 2011 Jul;103(3):759-64.

Fouladi M, Gururangan S, Moghrabi A, Phillips P, Gronewold L, Wallace D, Sanford RA, Gajjar A, Kun LE, Heideman R. Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer. 2009 Jul 15;115(14):3243-53.

Shih C, Hale GA, Gronewold L, Tong X, Gilger EA, Srivastava DK, Kun LE, Gajjar A, Fouladi M. High-Dose Chemotherapy with Autologous Stem Cell Rescue for Children with Recurrent Malignant Brain Tumors. Cancer. Mar 15;112(6):1345-53.

Fouladi M, Nicholson S, Zhou T, Laningham F, Helton K, et al. A Phase II Study of the Farnesyl Transferase Inhibitor, Tipifarnib, in Children with Recurrent or Progressive High Grade Glioma, Medulloblastoma/PNET or Brainstem Glioma: A Children’s Oncology Group Study. Cancer. 2007 Dec 1;110(11):2535-41.

Fouladi M, Laningham F, Wu J, O’Shaughnessy M, Molina K, Broniscer A, Spunt SL, Stewart CF, Houghton PJ, Gilbertson RJ, Furman WL. Phase I Study of Everolimus (RAD001) in Pediatric Patients with Refractory Solid Tumors. J Clin Oncol. 2007 Oct 20;25(30):4806-12.

Morris B, Gajjar A, Okuma, J, Yutaka Y, Wallace D, Kun L, Merchant T, Fouladi M, Broniscer A, Robison L, Hudson M. Survival and Late Mortality in Long-term Survivors of Pediatric Central Nervous System Tumors. J Clin Oncol. 2007 Apr 20;25(12):1532-8.

Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, Woo S, Wheeler G, Ahern V, Krasin MJ, Fouladi M, Broniscer A, Krance R, Hale GA, Stewart CF, Dauser R, Sanford RA, Fuller C, Lau C, Boyett JM, Wallace D, Gilbertson RJ. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicenter trial.Lancet Oncol. 2006 Oct;7(10):813-20. Erratum in: Lancet Oncol. 2006 Oct;7(10):797.

Fouladi M, Blaney S, Young Poussaint T, Freeman B, McLendon R, Fuller C, Adesina A, Hancock M, Danks M, Ivy P, Stewart C, Gajjar A. A Phase II study of oxaliplatin in children with recurrent or refactory medulloblastoma (MB), supratentorial primitive neuroectodermal tumors (SPNET) and atypical teratoid rhabdoid tumors (ATRT): A Pediatric Brain Tumor Consortium Study. Cancer. 2006 107:2291-2297.

Fouladi M. Histone deacetylase inhibitors. Cancer Invest. 2006 (5):521-7.

Merchant T, Fouladi M. Ependymoma: New therapeutic approaches including radiation and chemotherapy. J Neuro Oncol. 2006 3:287-99.

Grants

Phase I Study of MK2206, an AKT inhibitor, in Children with Recurrent Solid Tumors or Leukemia. CancerFree Kids Pediatric Cancer Research Alliance. Jun 2011 - Jun 2012.

CERN Clinical Trials Network-Per Patient. Univ of Texas / Anderson Cancer Center. Jul 2009 - Jun 2012.

Pediatric Brain Tumor Consortium. National Institutes of Health. Apr 2008 - Apr 2012. #U01CA098543.

Children's Oncology Group. National Institutes of Health. Mar 2011 - Mar 2012. #U10 CA 98543.

Related Professionals

Doctors & Researchers

© 1999-2011 Cincinnati Children's Hospital Medical Center

3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462 | TTY:1-513-636-4900